

Ste-Luce, February 22, 2023

Dear Concerned Party,

In order for MAG-O3™, MaxSimil®, and all Monoglyceride Omega-3 products containing EPA, DHA and/or DPA to accurately represent the material used in Dr. Fortin's clinical trials, they must be manufactured according to Dr. Fortin's patents. The MaxSimil® oil (Monoglyceride (MAG) omega-3 fish oil manufactured by Neptune Wellness Solutions inc.) used in the clinical trial NCT03897660¹ was manufactured in compliance with Dr. Fortin's patents (CA 2672513 and CA 2677670) and is identical to the MAG-O3™ monoglyceride omega-3 rich fish oil sold by High 5 Health Group. It is important to note that the Triglyceride (TG) form of omega-3 oil referenced in the cited clinical trial is also known as re-esterified triglyceride (rTG) omega-3 oil.

Best regards,



Samuel Fortin Ph. D., President, SCF Pharma

¹ Chevalier, L., Vachon, A. and Plourde, M., 2021. Pharmacokinetics of supplemental omega-3 fatty acids esterified in monoglycerides, ethyl esters, or triglycerides in adults in a randomized crossover trial. *The Journal of Nutrition*, 151(5), pp.1111-1118.